Unexpected Synergy Reveals New Therapeutic Strategy in SCLC
- PMID: 30975441
- DOI: 10.1016/j.tips.2019.03.005
Unexpected Synergy Reveals New Therapeutic Strategy in SCLC
Abstract
DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.
Keywords: PARP inhibitor; PD-1; PD-L1; SCLC; checkpoint kinase 1 inhibitor; immune checkpoint blockade.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment on
-
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18. Cancer Discov. 2019. PMID: 30777870 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
